Clovis Oncology to Pay the SEC $20 Million for Misleading Investors

Clovis Oncology will pay more than $20 million in penalties to settle charges that Chief Executive Officer Patrick Mahaffy and its former Chief Financial Officer Erle Mast misleading investors about the company’s lung cancer treatment leading up to a public offering of stock.